An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Trial Profile

An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Eribulin (Primary) ; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 27 Jun 2017 According to Eisai Co Ltd media release, in alignment with Chinese regulations the company has withdrawn drug application for anticancer agent eribulin mesylate (Halaven) in China in order to submit additional documentation. The company will resubmit the NDA as soon as the additional documentation is prepared. NDA was submitted in July 2016 based on the data from this trial.
    • 05 Aug 2016 Primary endpoint has been met. (Progression-Free Survival (PFS) of Eribulin Arm over the comparator treatment vinorelbine: Time to disease progression), as per Eisai media release.
    • 05 Aug 2016 Status changed from active, no longer recruiting to completed, as per Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top